These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34508604)

  • 1. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
    J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
    Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
    J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
    Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
    Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-related fatigue among patients with advanced cancer receiving immune-checkpoint inhibitors: a prospective study.
    Yennurajalingam S; Thomas L; Stanton PA; Lu Z; de Moraes AR; Bruera E
    Support Care Cancer; 2024 Jun; 32(7):459. PubMed ID: 38918253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
    J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
    Zhu J; Luo M; Liang D; Gao S; Zheng Y; He Z; Zhao W; Yu X; Qiu K; Wu J
    Int Immunopharmacol; 2022 Sep; 110():109053. PubMed ID: 35978507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.
    Pierrard J; Seront E
    Curr Oncol; 2019 Dec; 26(6):395-403. PubMed ID: 31896938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.
    Farooq MZ; Aqeel SB; Lingamaneni P; Pichardo RC; Jawed A; Khalid S; Banskota SU; Fu P; Mangla A
    JAMA Netw Open; 2022 Apr; 5(4):e227722. PubMed ID: 35438755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis.
    Veccia A; Kostine M; Tison A; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Caffo O; Paolazzi G; Bortolotti R; Cornec D; Berti A
    Joint Bone Spine; 2022 Jul; 89(4):105403. PubMed ID: 35508288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.